Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2887)	4/1/2020 5:47:06 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3557

Combination where Favipiravir (antiviral with some activity demonstrated in few subjects) is control arm: Actemra clinicaltrials.gov

To: Miljenko Zuanic who wrote (2887)	4/1/2020 9:54:36 PM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

There is a difference. Ebola had >50% mortality, and the other treatment being used as control (ZMAPP) was already thought to actually work. There is nothing known to work for this disease, and certainly not for severe patients. What is the control you want to give? Some other novel drug to compare it to? I'm sure they are happy to do so whenever someone comes up with one, but we don't have time to wait for that. The point of this trial is patients are given Standard of Care, vs. Standard of Care plus Kevzara. Not Kevzara vs. they let you die. They are not given a death sentence in the control group. The standard of care currently is oxygen supply and ventilation. Many have been helped to survive this disease with that (but too many lost). I don't know what you imagine is the alternative, but this trial will prove whether it works. Unlike the crappy open label studies of hydroxychloroquine where we are left not knowing for sure what the heck it is doing or not doing. So everyone treats with that but people keep dying. It is important to actually prove something works.